FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005652017> ?p ?o ?g. }

• W2005652017 endingPage "72" @default.
• W2005652017 startingPage "66" @default.
• W2005652017 abstract "In Gaucher disease (GD), acid-β-glucosidase (GBA1) gene mutations result in defective glucocerebrosidase and variable combinations of hematological, visceral, and diverse bone disease. Osteopenia is highly prevalent, but its age of onset during the natural course of GD is not known. It is also unclear if the degree of improvement in osteopenia, secondary to imiglucerase enzyme therapy, differs by the age of the patient. We hypothesized that osteopenia develops early in life, during the natural course of type 1 Gaucher disease (GD1), and that its response to treatment is maximal during this period. We examined data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry of patients treated with imiglucerase between the ages of 5 and 50 years. Lumbar spine bone mineral density (BMD) (determined by dual-energy X-ray absorptiometry (DXA) and expressed as Z-scores) at baseline and for up to 10 years on imiglucerase were analyzed in children (ages ≥ 5 to < 12 years), adolescents (≥ 12 to < 20 years), young adults (≥ 20 to < 30 years), and older adults (≥ 30 to < 50 years). BMD was correlated with other disease characteristics. Pre-treatment, descriptive statistics were applied to 5-year age categories. Non-linear mixed effects regression models were used to analyze DXA Z-scores over time after treatment with imiglucerase. Pre-treatment, low BMD was prevalent in all age groups, most strikingly in adolescents. DXA Z-scores were at or below − 1 in 44% of children (n = 43), 76% of adolescents (n = 41), 54% of young adults (n = 56) and 52% of older adults (n = 171). The most common GBA1 genotype was N370S heteroallelic. Baseline hematological and visceral manifestations in the 4 age groups were similar. In children with DXA Z-scores ≤ − 1 at baseline, imiglucerase therapy for 6 years resulted in improvement of mean DXA Z-scores from − 1.38 (95% CI − 1.73 to − 1.03) to − 0.73 (95% CI − 1.25 to − 0.21); in young adults DXA Z-scores improved from − 1.95 (95% CI − 2.26 to − 1.64) to − 0.67 (95% CI − 1.09 to − 0.26). BMD also improved in older adults, but the magnitude of the improvement was lower compared to younger patients. Low bone density is common in GD1 with the highest prevalence rate in adolescence, a developmental period critical to attainment of peak bone mass. Imiglucerase results in amelioration of osteopenia in all age groups, with the greatest improvements in younger patients." @default.
• W2005652017 created "2016-06-24" @default.
• W2005652017 creator A5011703152 @default.
• W2005652017 creator A5020371999 @default.
• W2005652017 creator A5034053799 @default.
• W2005652017 creator A5034285627 @default.
• W2005652017 creator A5055529584 @default.
• W2005652017 creator A5061182342 @default.
• W2005652017 date "2011-01-01" @default.
• W2005652017 modified "2023-10-03" @default.
• W2005652017 title "Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults" @default.
• W2005652017 cites W1963573503 @default.
• W2005652017 cites W1976520248 @default.
• W2005652017 cites W1990109620 @default.
• W2005652017 cites W2035280943 @default.
• W2005652017 cites W2038186195 @default.
• W2005652017 cites W2044342522 @default.
• W2005652017 cites W2048121149 @default.
• W2005652017 cites W2051581262 @default.
• W2005652017 cites W2076584038 @default.
• W2005652017 cites W2076780197 @default.
• W2005652017 cites W2078865702 @default.
• W2005652017 cites W2085316805 @default.
• W2005652017 cites W2091356228 @default.
• W2005652017 cites W2114854638 @default.
• W2005652017 cites W2128241866 @default.
• W2005652017 cites W2136261265 @default.
• W2005652017 cites W2161236662 @default.
• W2005652017 cites W2307104008 @default.
• W2005652017 cites W4241545626 @default.
• W2005652017 cites W4246132361 @default.
• W2005652017 doi "https://doi.org/10.1016/j.bcmd.2010.10.011" @default.
• W2005652017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3019260" @default.
• W2005652017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21112800" @default.
• W2005652017 hasPublicationYear "2011" @default.
• W2005652017 type Work @default.
• W2005652017 sameAs 2005652017 @default.
• W2005652017 citedByCount "97" @default.
• W2005652017 countsByYear W20056520172012 @default.
• W2005652017 countsByYear W20056520172013 @default.
• W2005652017 countsByYear W20056520172014 @default.
• W2005652017 countsByYear W20056520172015 @default.
• W2005652017 countsByYear W20056520172016 @default.
• W2005652017 countsByYear W20056520172017 @default.
• W2005652017 countsByYear W20056520172018 @default.
• W2005652017 countsByYear W20056520172019 @default.
• W2005652017 countsByYear W20056520172020 @default.
• W2005652017 countsByYear W20056520172021 @default.
• W2005652017 countsByYear W20056520172022 @default.
• W2005652017 countsByYear W20056520172023 @default.
• W2005652017 crossrefType "journal-article" @default.
• W2005652017 hasAuthorship W2005652017A5011703152 @default.
• W2005652017 hasAuthorship W2005652017A5020371999 @default.
• W2005652017 hasAuthorship W2005652017A5034053799 @default.
• W2005652017 hasAuthorship W2005652017A5034285627 @default.
• W2005652017 hasAuthorship W2005652017A5055529584 @default.
• W2005652017 hasAuthorship W2005652017A5061182342 @default.
• W2005652017 hasBestOaLocation W20056520172 @default.
• W2005652017 hasConcept C126322002 @default.
• W2005652017 hasConcept C163276114 @default.
• W2005652017 hasConcept C1862650 @default.
• W2005652017 hasConcept C187212893 @default.
• W2005652017 hasConcept C205545832 @default.
• W2005652017 hasConcept C2776541429 @default.
• W2005652017 hasConcept C2776886416 @default.
• W2005652017 hasConcept C2777083390 @default.
• W2005652017 hasConcept C2779134260 @default.
• W2005652017 hasConcept C2779969927 @default.
• W2005652017 hasConcept C2780674200 @default.
• W2005652017 hasConcept C71924100 @default.
• W2005652017 hasConceptScore W2005652017C126322002 @default.
• W2005652017 hasConceptScore W2005652017C163276114 @default.
• W2005652017 hasConceptScore W2005652017C1862650 @default.
• W2005652017 hasConceptScore W2005652017C187212893 @default.
• W2005652017 hasConceptScore W2005652017C205545832 @default.
• W2005652017 hasConceptScore W2005652017C2776541429 @default.
• W2005652017 hasConceptScore W2005652017C2776886416 @default.
• W2005652017 hasConceptScore W2005652017C2777083390 @default.
• W2005652017 hasConceptScore W2005652017C2779134260 @default.
• W2005652017 hasConceptScore W2005652017C2779969927 @default.
• W2005652017 hasConceptScore W2005652017C2780674200 @default.
• W2005652017 hasConceptScore W2005652017C71924100 @default.
• W2005652017 hasIssue "1" @default.
• W2005652017 hasLocation W20056520171 @default.
• W2005652017 hasLocation W20056520172 @default.
• W2005652017 hasLocation W20056520173 @default.
• W2005652017 hasLocation W20056520174 @default.
• W2005652017 hasOpenAccess W2005652017 @default.
• W2005652017 hasPrimaryLocation W20056520171 @default.
• W2005652017 hasRelatedWork W2010009026 @default.
• W2005652017 hasRelatedWork W2407717434 @default.
• W2005652017 hasRelatedWork W2410706400 @default.
• W2005652017 hasRelatedWork W2412971612 @default.
• W2005652017 hasRelatedWork W2419618477 @default.
• W2005652017 hasRelatedWork W2567269117 @default.
• W2005652017 hasRelatedWork W2993364312 @default.
• W2005652017 hasRelatedWork W4241607577 @default.
• W2005652017 hasRelatedWork W4311965703 @default.

• next